by dyadic | Mar 27, 2024 | Press Releases
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...
by dyadic | Mar 26, 2024 | Press Releases
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) — Dyadic...
by dyadic | Mar 21, 2024 | Press Releases
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...
by dyadic | Mar 14, 2024 | Press Releases
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative...
by dyadic | Mar 11, 2024 | Press Releases
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The corrected release follows: JUPITER, Fla., March 11, 2024 (GLOBE...
by dyadic | Mar 11, 2024 | Press Releases
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the...
